BCL9L Antikörper (N-Term)

Produktnummer ABIN783409

Produktdetails anti-BCL9L Antikörper

Target: BCL9L (B-Cell CLL/lymphoma 9-Like (BCL9L))

Bindungsspezifität: N-Term

Reaktivität: Human, Maus, Ratte

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser BCL9L Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Enzyme Immunoassay (EIA)

Spezifität: This antibody detects Bcl-9-like protein at N-term. It is predicted to not cross-react with other Bcl family members. At least four isoforms of Bcl9L are known to exist, this antibody will detect all four.

Kreuzreaktivität (Details): Species reactivity (tested):Human, mouse, rat

Aufreinigung: Affinity chromatography purified via peptide column

Immunogen: 20 amino acid peptide near the amino terminus of human Bcl9L

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Buffer: PBS containing 0.02 % sodium azide

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Avoid repeated freezing and thawing.

Lagerung: 4 °C/-20 °C

Informationen zur Lagerung: Store at 2 - 8 °C for up to three months or (in aliquots) at -20 °C for longer.

Details zu BCL9L

Target: BCL9L (B-Cell CLL/lymphoma 9-Like (BCL9L))

Andere Bezeichnung: Bcl-9-Like Protein (BCL9L Produkte)

Synonyme: BCL9-2 antikoerper, DLNB11 antikoerper, B9L antikoerper, BC003321 antikoerper, bcl9-2 antikoerper, BCL9L antikoerper, B-cell CLL/lymphoma 9 like antikoerper, B cell CLL/lymphoma 9-like antikoerper, B-cell CLL/lymphoma 9-like antikoerper, BCL9L antikoerper, Bcl9l antikoerper, bcl9l antikoerper

Hintergrund: Bcl9L, a homolog of Bcl9, was initially identified through a bioinformatics screening. It is expressed in fetal brain, adult lung, eye and prostate, in addition to several types of tumors including pancreatic and prostate cancers. Bcl9L has been shown to interact with b-catenin, a target of the Wnt signaling pathway, and is required for enhanced ?-catenin-T-cell factor (TCF)-mediated transcription in colorectal tumor cells, possibly by translocating b-catenin to the nucleus. Other studies have indicated that Bcl9L expression correlates with high nuclear grade cancer phenotype and the expression of ErbB2/HER-2 in breast cancers, suggesting that activity may occur in other types of cancer. Bcl9L has also been shown to be critical for Wnt-mediate regulation of stem cell traits in colon epithelium and adenocarcinomas which are associated with tumor invasion, metastasis, and resistance to therapy.Synonyms: B-cell CLL/lymphoma 9-like protein, B-cell lymphoma 9-like protein, BCL9-like protein, BCL9L, DLNB11

Gen-ID: 283149

NCBI Accession: NP_872363

UniProt: Q86UU0

Pathways: Stem Cell Maintenance